We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
- Authors
Allqvist, Annika; Miura, Jun; Bertilsson, Leif; Mirghani, Rajaa
- Abstract
The antifungal drug ketoconazole (KTZ) is known as an inhibitor of, especially, the CYP3A subfamily, which catalyzes the metabolism of a large variety of drugs. Interactions between KTZ and CYP3A substrates have been reported both in vivo and in vitro. Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism. The inhibition of alprazolam and quinine metabolism was studied in an in vitro system of human liver microsomes (HLM), recombinant of CYP3A4 and CYP3A5. The concentrations of formed 3-hydroxyquinine and 4- and α-hydroxyalprazolam were measured by HPLC and LC-MS, respectively. Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5. The formation rate of 4-hydroxyalprazolam was higher than that of α-hydroxyalprazolam for each HLM, CYP3A4 and CYP3A5. KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism. Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC50 value of 0.16 μM for HLM, 0.04 μM for CYP3A4 and 0.11 μM for CYP3A5. The same enantiomer showed the lowest IC50 values of 0.11 μM for HLM and 0.04 μM for CYP3A5 with respect to alprazoalm 4-hydroxylation and also the same pattern for alprazolamα-hydroxylation, 0.13 μM for HLM and 0.05 μM for CYP3A5. Alprazolam metabolism (both α- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ 2S,4R, with IC50 values of 0.03 μM . Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. The present study showed that different KTZ enantiomers inhibit CYP3A4 and CYP3A5 to different degrees, indicating that structural differences among the enantiomers would be related to their inhibitory potency on these two enzymes.
- Subjects
ALPRAZOLAM; QUININE; ENANTIOMERS; METABOLISM; BIOCHEMISTRY; DRUG interactions
- Publication
European Journal of Clinical Pharmacology, 2007, Vol 63, Issue 2, p173
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-006-0230-z